In a saturated drug market, head-to-head superiority is manufactured by comparator selection.
With duopoly molecules clinically close, each side manufactures claims of superiority by choosing favorable comparator doses or outdated trial data — and litigates the rival's comparisons as false advertising.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
Novo's first head-to-head win over tirzepatide is manufactured by benchmarking against the lowest competitor dose rather than full-dose Zepbound.
With the molecules clinically close, the duopoly litigates each other's comparative superiority claims as false advertising rather than competing on data.
The duopoly is litigating head-to-head superiority claims built on favorable comparator selection, exactly the manufactured-comparison battlefield the theme describes.